Notably, anti-MSLN CAR-like NK cells demonstrated a more significant advantage in inhibiting tumor growth than MSLN×CD16A combined with CIML NK cell therapy did (P < 0.05), with this trend strengthening over time. The gene discussed is MSLN; the disease is neoplasm.